Catalent to Develop Biosimilars for Valerius Biopharma

Article

Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.

Catalent Pharma Solutions and Valerius Biopharma, a Swiss biopharmaceutical company, announced on May 14, 2018 that Catalent Biologics will provide cell line development and support cGMP manufacturing activities from Phase I through to commercial stages at its biologics manufacturing facility in Madison, WI for Valerius’ biosimilar products.

The project will use Catalent’s GPEx technology, which creates production cell lines in a variety of mammalian host cells. The company reported in a press release that, to date, more than 460 different monoclonal antibodies and monoclonal antibody fusions, and more than 50 different recombinant proteins, have been produced using the GPEx system, achieving fed-batch production titers of over 7 g/L.

Valerius Biopharma was founded to develop biosimilar products as alternatives to high-priced biologics, for indications where there is a substantial medical need. The company’s current product pipeline includes four biosimilar products in different development stages.

Source: Catalent Pharma

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.